NEW YORK (360Dx) – French pharmaceutical firm Pierre Fabre today announced it and Roche have extended a companion diagnostic agreement for Pierre Fabre's oncology drug candidate.
The original deal was for Roche to develop a prototype immunohistochemistry assay to be used as a CDx for W0101, Pierre Fabre's antibody drug conjugate product candidate targeting insulin-like growth factor 1 receptor. The collaboration has been extended to the retrospective determination of IGF-1R expression in patients enrolled in the international Phase I/ II clinical study of patients with relapsed or refractory solid tumors. The in-human clinical trial was launched in 2017.
Financial and other terms of the extended deal were not disclosed.